Dyslipidemia and atypical antipsychotic drugs
- PMID: 15600382
Dyslipidemia and atypical antipsychotic drugs
Abstract
Dyslipidemia is an increasing problem in most industrialized societies and is a risk factor for coronary heart disease (CHD). Imbalances in individual lipid components, including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and serum triglycerides, have each been shown to contribute to this increased risk. Certain psychiatric patient populations, such as those afflicted with schizophrenia, are of particular concern. Psychiatric patients with schizophrenia are naturally at increased risk for dyslipidemia and obesity, in part due to poor diet and sedentary lifestyle, but these conditions can be exacerbated by some antipsychotic medications. Clozapine and olanzapine, for example, appear to be associated with hyperlipidemia, which may be associated with changes in body weight. Other, newer antipsychotic agents may exhibit less liability for weight gain and the development of dyslipidemia. This review is intended to briefly highlight the association between dyslipidemia and cardiovascular disease, the changes in serum lipids associated with some antipsychotic agents, and how these changes in serum lipids affect the monitoring of schizophrenia patients.
Similar articles
-
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.J Clin Psychopharmacol. 2008 Apr;28(2):132-7. doi: 10.1097/JCP.0b013e318166c4f7. J Clin Psychopharmacol. 2008. PMID: 18344722
-
Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.Schizophr Res. 2005 Dec 1;80(1):55-9. doi: 10.1016/j.schres.2005.05.001. Epub 2005 Jun 17. Schizophr Res. 2005. PMID: 15964176 Clinical Trial.
-
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.J Clin Psychiatry. 2004;65 Suppl 18:47-56. J Clin Psychiatry. 2004. PMID: 15600384 Clinical Trial.
-
The effects of antipsychotic therapy on serum lipids: a comprehensive review.Schizophr Res. 2004 Sep 1;70(1):1-17. doi: 10.1016/j.schres.2004.01.014. Schizophr Res. 2004. PMID: 15246458 Review.
-
[Metabolic risk during antipsychotic treatment in patients with schizophrenia].Psychiatr Pol. 2007 Jul-Aug;41(4):457-72. Psychiatr Pol. 2007. PMID: 18046977 Review. Polish.
Cited by
-
The health benefits and challenges of exercise training in persons living with schizophrenia: a pilot study.Brain Sci. 2013 May 24;3(2):821-48. doi: 10.3390/brainsci3020821. Brain Sci. 2013. PMID: 24961427 Free PMC article.
-
Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.Mol Psychiatry. 2008 Oct;13(10):918-29. doi: 10.1038/mp.2008.40. Epub 2008 Apr 15. Mol Psychiatry. 2008. PMID: 18414407 Free PMC article. Review.
-
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug Saf. 2012 Oct 1;35(10):819-36. doi: 10.1007/BF03261978. Drug Saf. 2012. PMID: 22967188
-
Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?J Nutr Health Aging. 2012;16(6):557-61. doi: 10.1007/s12603-012-0057-5. J Nutr Health Aging. 2012. PMID: 22659997 Review.
-
Paliperidone extended-release: safety and tolerability from a metabolic profile perspective.Clin Drug Investig. 2013 Dec;33(12):867-76. doi: 10.1007/s40261-013-0100-2. Clin Drug Investig. 2013. PMID: 24241935 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical